Search Videos and More
Video
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data presented by Dana-Farber's Ann Partridge, MD.
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Ada Waks, MD Presents Results of the MARGOT Study
Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.
News
Dana-Farber Research News 12.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 through November 30.
News
Dana-Farber Research News 12.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 through November 15.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
Symposium
2024 ASH Highlights
Learn more about what Dana-Farber physician-scientists will be covering at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 42 of its researchers have been named to the Highly Cited Researchers list of 2024, released today by the Institute for Scientific Information at Clarivate.
News
First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber
Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum resistant ovarian cancer.
News
Dana-Farber Research News 11.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 16 through October 31.